Tam Constantine S, Khouri Issa
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Hematol Oncol. 2009 Jun;27(2):53-60. doi: 10.1002/hon.884.
The majority of patients diagnosed with chronic lymphocytic leukaemia (CLL) will ultimately die of their disease. Stem cell transplantation (SCT) remains the only treatment modality capable of cure, but has traditionally been associated with very high morbidity and mortality. We review the results of myeloablative autologous and allogeneic SCT in CLL, discuss the evolution of the new non-myeloablative approaches, and make recommendations for when SCT should be considered in patients with CLL.
大多数被诊断为慢性淋巴细胞白血病（CLL）的患者最终会死于该疾病。干细胞移植（SCT）仍然是唯一能够治愈该病的治疗方式，但传统上一直伴随着非常高的发病率和死亡率。我们回顾了CLL患者中清髓性自体和异基因SCT的结果，讨论了新的非清髓性方法的发展，并就何时应考虑对CLL患者进行SCT提出建议。
